NCT04987554

Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2

Status unknown NA Last updated 3 August 2021

What this trial tests

NA trial testing glycophosphopeptical AM3 in SARS-CoV-2 Infection in 120 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
31 December 2021

31 December 2022

Quick facts

Lead sponsor	University of Valladolid
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	1 April 2021
Primary completion	31 December 2021
Estimated completion	31 December 2022
Sites	1 location across Spain

Drugs / interventions tested

• glycophosphopeptical AM3
• Placebo

Conditions studied

• SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

University of Valladolid

Who can join

Adults 18 to 80, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: In late 2019, a novel human coronavirus was detected in Wuhan, China, causing an outbreak of the severe acute respiratory syndrome - Coronavirus 2 (SARS-CoV-2). The disease that SARS-CoV-2 causes was named coronavirus disease 2019 (COVID-19). The virus rapidly spread throughout China and beyond, causing a public health challenge of global concern. Today, the availability of safe and effective drugs to treat COVID-19 remains limited, and symptomatic supportive treatments are the foundations of care. A natural glycophosphopeptical, AM3 has been shown to effectively improve the progression of infectious respiratory diseases with no side effects. In this context, AM3 could maintain an adequate immune status and serve as a therapeutic tool against COVID-19.

Study Aim: The effect of AM3 supplementation on the progression of COVID-19 patients. To evaluate the existence of significant differences between control and intervention groups in the progression of severe COVID-19 disease.

Methods: Double-blind randomized controlled clinical trial in collaboration with the Health Care Management of Soria. At the start of the trial, eligible patients will be randomized in a 1:1 ratio into two intervention and control groups. Block randomization with participants based on gender will be used. 120 patients with a confirmed diagnosis of COVID-19 by PCR and/or antigen testing will be randomized to the control group (placebo treatment) or experimental group (AM3 treatment), respectively. Patients will be randomly divided into two groups, the AM3 supplementation group (n=60) and the control group (n=60). The intervention group will be administered 2 indistinct capsules of AM3 (3 g/day of AM3) for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach. The control group will be administered a placebo of identical appearance of 2 indistinct capsules for a single daily intake in the morning, same dose as the experimental group (3 g/day of placebo), for 30 consecutive days.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. The Use of Prebiotics from Pregnancy and Its Complications: Health for Mother and Offspring-A Narrative Review.
   García-Montero C, Fraile-Martinez O, Rodriguez-Martín S, Saz JV, et al · · 2023 · cited 10× · PMID 36981075 · DOI 10.3390/foods12061148